desvenlafaxine
Clinical pharmacology
| Drug UPDATES: KHEDEZLA (desvenlafaxine) Extended-release Tablets, for oral use [Drug information / PDF] Dosing: Click (+) next to Dosage and Administration section (drug info link) Initial U.S. Approval: 2013 Mechanism of Action: The exact mechanism of the antidepressant action of KHEDEZLA is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). |
Indications and usage
| INDICATIONS AND USAGE: KHEDEZLA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD). |
Dosage and administration
| [Drug information / PDF] Dosing: Click (+) next to Dosage and Administration section (drug info link) |
Reference(s)
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
